ClinicalTrials.Veeva

Menu

Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.

F

Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon

Status and phase

Terminated
Phase 2

Conditions

Myelodysplastic Syndrome

Treatments

Drug: Darbepoetin alfa

Study type

Interventional

Funder types

Other

Identifiers

NCT01039350
2005-002414-38 (EudraCT Number)
GEE200401

Details and patient eligibility

About

This is an open-label, single-arm, multicentre, prospective study of darbepoetin alfa to treat anaemia in patients with low and intermediate-1 IPSS risk MDS. The study will consist of a 14-day screening period followed by a maximum 24-week treatment period and a final visit.

Full description

This is an open-label, single-arm, multicentre, prospective study of darbepoetin alfa to treat anaemia in patients with low and intermediate-1 IPSS risk MDS. The study will consist of a 14-day screening period followed by a maximum 24-week treatment period and a final visit. Darbepoetin alfa will be initiated at a dose of 300 mcg QW SC over a period of 8 weeks. After 8 weeks, erythroid response will be evaluated, and treatment algorithm adapted to it.

The study treatment period will last for a maximum of 24 weeks. The treatment will end at the start of week 24. If the scheduled 24-week treatment period is not completed, it will end during the week of the last administration of the study drug.

The follow-up period will last for a minimum of 4 weeks and a maximum of 8 weeks after the last dose of darbepoetin alfa.

Subjects will be stratified at enrolment according to IPSS (low risk versus intermediate-1 risk).

Enrollment

80 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ³ 18 years
  • Low or intermediate-1 risk MDS according to IPSS, and FAB classification of RA, RARS, or RAEB with blasts £ 10%
  • Predictive variables of good response (serum erythropoietin levels < 500 IU/l and transfusion requirements < 2 packed RBC/month over the preceding 2 months)
  • Anaemia (Hb £ 10 g/dL), confirmed in the 14 days before day 1 of the study
  • Life expectancy of at least 6 months
  • ECOG Performance status score of 0, 1, or 2
  • Subject must sign and date the Informed Consent (approved by a Clinical Research Ethics Committee - CREC), before any study-specific procedure is performed

Exclusion criteria

  • Known history of convulsive disorders
  • Poorly controlled hypertension (diastolic blood pressure > 100 mmHg) at screening
  • Inadequate liver function (total bilirubin > two times the upper limit of the normal range (ULN), and liver enzymes (ALT, AST) > two times ULN)
  • Inadequate renal function (serum creatinine concentration > 2 mg/dL)
  • Ferritin < 100 ng/ml or transferrin saturation index (TSI) < 16%; Vitamin B12 deficiency (< 200 pg/ml) or folate deficiency (< 2 ng/ml)
  • Clinically-relevant haemorrhages
  • Haemolytic anaemia
  • Cardiac condition: uncontrolled angina, congestive heart failure, or uncontrolled cardiac arrhythmia
  • Clinically significant systemic infection or chronic inflammatory disease present at time of screening
  • Any concomitant therapy used to treat MDS (including other growth factors than those described as part of this protocol, chemotherapy, antibody-based cancer treatment, hormonal therapy, interferon, and interleukins)
  • Treatment with rHuEPO or darbepoetin alfa over the 4 weeks prior to Day 1 of the study
  • More than 2 RBC transfusions over the 28 days prior to Day 1 of the study
  • Pregnant or breast feeding women
  • Subjects of childbearing-potential who do not take adequate contraceptive measures, in the opinion of the investigator
  • Known hypersensitivity to any mammal-derived recombinant product

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

16

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems